Home › Companies › Halozyme Therapeutics, Inc. › 2025-2026

Halozyme Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Halozyme Therapeutics, Inc.’s Form 8-K, filed May 7, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

4Ballot items
594Asset managers
2,948Fund votes
May 5, 2026Meeting date

Results at a glance

Meeting of May 5, 2026: 4 items on Halozyme Therapeutics, Inc.’s Form 8-K, filed May 7, 2026: 2 approved · 2 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Halozyme Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Halozyme Therapeutics, Inc.

These tallies are Halozyme Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 7, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Halozyme Therapeutics, Inc. — official shareholder meeting results, meeting held May 5, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Bernadette Connaughton	89,053,734	5,068,160	127,131	--	9,889,219	95%	Not verified	—
Elect Director: Matthew L. Posard	82,739,433	10,236,878	1,272,714	--	9,889,219	89%	Not verified	—
2. The advisory vote on the compensation of the Company's named executive officers	84,682,518	9,311,426	255,081	--	9,889,219	90%	Approved	—
3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026	103,197,579	849,433	91,232	--	--	99.1%	Approved	—

Source: Halozyme Therapeutics, Inc., Form 8-K, filed with the SEC on May 7, 2026 — read the filing on EDGAR.

How asset managers voted at the Halozyme Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 594 asset managers that disclosed a Halozyme Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Bernadette Connaughton

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 89,053,734AGAINST: 5,068,160

Details: description as filed, official tally, votes by 143 asset managers

Description as filed by funds: Election of Class I Directors: Bernadette Connaughton

Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 89,053,734 for, 5,068,160 against, per its Form 8-K filed May 7, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 143 asset managers below reported 45,052,087 for, 1,629,505 against, 31,020 abstained, 90 not voted.

FOR

FOR: 45,052,087AGAINST: 1,629,505ABSTAIN: 31,020NOT VOTED: 90

Largest asset managers voting on “Election of Class I Directors: Bernadette Connaughton” at Halozyme Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,406,613	11	For
BlackRock	7,468,246	0	For
Fidelity	2,427,364	0	For
Invesco	2,371,379	0	For
State Street	2,337,907	0	For
First Trust	1,491,893	0	For
John Hancock	137,158	1,168,773	Mixed
Charles Schwab	1,257,706	0	For
Federated Hermes	1,113,851	0	For
Capitol Series Trust	898,255	0	For
Delaware/Macquarie	875,241	0	For
Pacer Funds Trust	849,734	0	For
Capital Group	830,385	0	For
Putnam	561,194	0	For
TIAA	551,184	0	For
Dimensional	521,318	0	For
WILLIAM BLAIR FUNDS	433,965	0	For
Bridge Builder Trust	313,876	101,043	Mixed
Jackson National	407,549	0	For
Nationwide	380,986	0	For
EA Series Trust	379,284	0	For
Calamos	349,930	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	347,050	0	For
Victory Capital	325,289	0	For
JANUS INVESTMENT FUND	321,070	0	For

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.

2. Elect Director: Matthew L. Posard

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 82,739,433AGAINST: 10,236,878

Details: description as filed, official tally, votes by 143 asset managers

Description as filed by funds: Election of Class I Directors: Matthew L. Posard

Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew L. Posard”): 82,739,433 for, 10,236,878 against, per its Form 8-K filed May 7, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 143 asset managers below reported 42,500,283 for, 4,181,306 against, 31,023 abstained, 90 not voted.

FOR

FOR: 42,500,283AGAINST: 4,181,306ABSTAIN: 31,023NOT VOTED: 90

Largest asset managers voting on “Election of Class I Directors: Matthew L. Posard” at Halozyme Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	11,400,139	6,482	3	For
BlackRock	7,468,246	0	0	For
Fidelity	2,427,364	0	0	For
Invesco	2,371,379	0	0	For
State Street	20,564	2,317,343	0	Against
First Trust	1,491,893	0	0	For
John Hancock	137,158	1,168,773	0	Mixed
Charles Schwab	1,257,706	0	0	For
Federated Hermes	1,113,851	0	0	For
Capitol Series Trust	898,255	0	0	For
Delaware/Macquarie	875,241	0	0	For
Pacer Funds Trust	849,734	0	0	For
Capital Group	830,385	0	0	For
Putnam	561,194	0	0	For
TIAA	551,184	0	0	For
Dimensional	521,318	0	0	For
WILLIAM BLAIR FUNDS	433,965	0	0	For
Bridge Builder Trust	313,876	101,043	0	Mixed
Jackson National	407,549	0	0	For
Nationwide	380,986	0	0	For
EA Series Trust	379,284	0	0	For
Calamos	349,930	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	347,050	0	0	For
Victory Capital	325,289	0	0	For
JANUS INVESTMENT FUND	321,070	0	0	For

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.

3. 2. The advisory vote on the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 15 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%

FOR: 84,682,518AGAINST: 9,311,426

Details: description as filed, official tally, votes by 594 asset managers

Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.

Halozyme Therapeutics, Inc.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 84,682,518 for, 9,311,426 against — passed, per its Form 8-K filed May 7, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 143 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at Halozyme Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,406,613	10	For
BlackRock	7,468,246	0	For
Fidelity	2,427,364	0	For
Invesco	2,371,379	0	For
State Street	20,673	2,317,234	Against
First Trust	1,491,893	0	For
John Hancock	1,305,931	0	For
Charles Schwab	1,257,706	0	For
Federated Hermes	1,113,851	0	For
Capitol Series Trust	898,255	0	For
Delaware/Macquarie	875,241	0	For
Pacer Funds Trust	849,734	0	For
Capital Group	830,385	0	For
Putnam	561,194	0	For
TIAA	551,184	0	For
Dimensional	521,318	0	For
WILLIAM BLAIR FUNDS	433,965	0	For
Bridge Builder Trust	414,919	0	For
Jackson National	407,549	0	For
Nationwide	380,986	0	For
EA Series Trust	379,284	0	For
Calamos	349,930	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	347,050	0	For
Victory Capital	325,289	0	For
JANUS INVESTMENT FUND	321,070	0	For

Fund voting reports, all 143 managers: 44,000,700 for, 2,614,702 against, 31,020 abstained, 120 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 481 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at Halozyme Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	3,386,988	1,579	For
Invesco	3,056,452	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,468,793	0	For
State Street	53,662	2,409,195	Against
SNYDER CAPITAL MANAGEMENT L P	2,153,875	0	For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	2,098,221	0	For
Boston Partners	2,028,881	0	For
Janus Henderson	1,845,794	0	For
AllianceBernstein	1,691,604	0	For
JUPITER ASSET MANAGEMENT LTD	1,567,242	0	For
Federated Hermes	1,534,163	0	For
FULLER & THALER ASSET MANAGEMENT, INC.	1,344,686	0	For
Charles Schwab	1,276,616	0	For
GW&K Investment Management, LLC	228,358	0	For
CONGRESS ASSET MANAGEMENT CO	1,200,563	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	1,125,605	0	For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	1,095,740	0	For
Stephens Investment Management Group LLC	1,005,872	0	For
Vanguard	949,698	0	For
Northern Trust	924,622	0	For
Putnam	846,808	0	For
Capital Group	830,385	0	For
LOS ANGELES CAPITAL MANAGEMENT LLC	753,716	0	For
UBS	0	644,161	Against
Handelsbanken Fonder AB	591,869	0	For

Institutional-manager reports, all 481 managers: 51,128,132 for, 4,522,966 against, 94,279 abstained, 22,847 not voted, 1,030,053 mixed. Showing the 25 largest; see all in the interactive database.

4. 3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.1% Approved · of votes cast

FOR 99.1%

FOR: 103,197,579AGAINST: 849,433

Details: description as filed, official tally, votes by 143 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Halozyme Therapeutics, Inc.’s own tally for this item (“3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 103,197,579 for, 849,433 against — passed, per its Form 8-K filed May 7, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Halozyme Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 143 asset managers below reported 46,674,990 for, 6,602 against, 31,020 abstained, 90 not voted.

FOR

FOR: 46,674,990AGAINST: 6,602ABSTAIN: 31,020NOT VOTED: 90

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at Halozyme Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,400,153	6,471	For
BlackRock	7,468,246	0	For
Fidelity	2,427,364	0	For
Invesco	2,371,379	0	For
State Street	2,337,798	109	For
First Trust	1,491,893	0	For
John Hancock	1,305,931	0	For
Charles Schwab	1,257,706	0	For
Federated Hermes	1,113,851	0	For
Capitol Series Trust	898,255	0	For
Delaware/Macquarie	875,241	0	For
Pacer Funds Trust	849,734	0	For
Capital Group	830,385	0	For
Putnam	561,194	0	For
TIAA	551,184	0	For
Dimensional	521,318	0	For
WILLIAM BLAIR FUNDS	433,965	0	For
Bridge Builder Trust	414,919	0	For
Jackson National	407,549	0	For
Nationwide	380,986	0	For
EA Series Trust	379,284	0	For
Calamos	349,930	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	347,050	0	For
Victory Capital	325,289	0	For
JANUS INVESTMENT FUND	321,070	0	For

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.

Not shown here: this season’s fund filings also report 1 item from the meeting of May 1, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest Halozyme Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 118,523,000 shares outstanding at the time of that meeting.

Fund voting reports: top Halozyme Therapeutics, Inc. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	9.62%
2	BlackRock	6.30%
3	Fidelity	2.05%
4	Invesco	2.00%
5	State Street	1.97%
6	First Trust	1.26%
7	John Hancock	1.10%
8	Charles Schwab	1.06%
9	Federated Hermes	0.94%
10	Capitol Series Trust	0.76%

Institutional-manager reports: top Halozyme Therapeutics, Inc. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	2.86%
2	Invesco	2.58%
3	GEODE CAPITAL MANAGEMENT, LLC	2.08%
4	State Street	2.08%
5	SNYDER CAPITAL MANAGEMENT L P	1.82%
6	WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	1.77%
7	Boston Partners	1.71%
8	Janus Henderson	1.56%
9	AllianceBernstein	1.43%
10	JUPITER ASSET MANAGEMENT LTD	1.32%

Reported Halozyme Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Halozyme Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	11.19%	13F
Vanguard Group	9.76%	13F
State Street Corporation	5.11%	DEF14A
Invesco	3.39%	13F
Morgan Stanley	2.24%	13F
Helen I. Torley	1.86%	DEF14A
Dimensional Fund Advisors	1.75%	13F
D.E. Shaw	1.60%	13F
Two Sigma	1.34%	13F
Charles Schwab	1.09%	13F

Percentages above are of 118,523,000 shares outstanding, as reported by Halozyme Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Halozyme Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Halozyme Therapeutics, Inc.'s shareholder meeting held May 5, 2026, in the 2025-2026 proxy season, 594 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 2,948 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — Halozyme Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Halozyme Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 7, 2026.

Halozyme Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.